Default company panoramic image
Logo

VitamFero

VitamFero develops new proprietary live attenuated vaccines especially against animal and human parasitoses

  • Stage Product In Development
  • Industry Biotechnology
  • Location Tours, Centre, France
  • Currency EUR
  • Founded October 2005
  • Employees 9
  • Website vitamfero.com

Company Summary

VitamFero holds a proprietary vaccine platform and a unique know-how based on the establishment and use of live attenuated protozoan parasite strains. Perfectly described and controlled, these strains and their recombinant derivatives are the API of anti-infectious vaccines, currently developed mostly against certain animal and human parasitoses such as toxoplasmosis or malaria the prevention of which still represents huge medical unmet need.

Team

  • Default avatar
    Pascal Gérard BRETON
    President and Chief Executive Officer

    Co-founder of VitamFero, +20 year experience in the pharmaceutical and biopharmaceutical industry (UPSA, BMS, Halisol-Virsol, IDM Pharma, SGS LSS)

  • Default avatar
    Edouard SECHE
    Head of Research

    Co-founder of VitamFero, 10 year experience in the biopharmaceutical industry

  • Default avatar
    Didier ROY
    Head of Development

    24 year experience in the pharmaceutical and biopharmaceutical industry (UPSA, BMS, Halisol-Virsol)

Advisors

  • Default avatar
    Dechert (Paris, France) LLP
    Lawyer
    Unconfirmed
    Default avatar
    In Extenso (Deloitte) (Tours, France)
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    CapDecisif Management
    Unconfirmed
    Default avatar
    G1J Ile-de-France
    Unconfirmed
    Default avatar
    Val de France Angels (16 Business Angels)
    Unconfirmed